Canal-U

Mon compte

Résultats de recherche

Nombre de programmes trouvés : 14
Conférences

le (58m17s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Will we be able to answer the question of HDL as a therapeutic target after the CETP inhibitor trials? (Robert ROSENSON)

... disease and to identify and select new drug biotargets.➢ One major question relates to the value of biomarker-guided and/or risk guided therapy and how to design appropriate trials to test these therapeutic strategies. Should therapy be targeted to...
Voir la vidéo
Label UNT Conférences

le (17m30s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measures

...Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measuresSpeaker: Michael FELKER, Durham, USAAbstract : Biomarker...
Voir la vidéo
Conférences

le (14m26s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Will we be able to answer the question of HDL as a therapeutic target after the CETP inhibitor trials? (Eric STROES)

... disease and to identify and select new drug biotargets.➢ One major question relates to the value of biomarker-guided and/or risk guided therapy and how to design appropriate trials to test these therapeutic strategies. Should therapy be targeted to...
Voir la vidéo

 
FMSH
 
Facebook Twitter
Mon Compte